4DMT to Participate in Upcoming Investor Conferences

Rhea-AI Summary

4D Molecular Therapeutics (Nasdaq: FDMT) announced management will present and hold one-on-one investor meetings at two May 2026 healthcare conferences: BofA Securities 2026 Healthcare Conference on May 13, 2026 at 1:40 p.m. PT, and RBC 2026 Global Healthcare Conference on May 19, 2026 at 2:35 p.m. ET. Archived webcasts will be available for up to one year on the company’s Investors website.

Argus May 4 session

+3.85% close to close Open Argus

Details

News Market Reaction – FDMT

On May 4, the day this news came out, FDMT closed 3.85% above the previous close.

Data tracked by StockTitan Argus for the May 4 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in May.

BofA Securities 2026 Healthcare Conference

Presentation Date:	Wednesday, May 13, 2026
Presentation Time:	1:40 p.m. PT

RBC 2026 Global Healthcare Conference

Presentation Date:	Tuesday, May 19, 2026
Presentation Time:	2:35 p.m. ET

Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.

About 4DMT         

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will 4D Molecular Therapeutics (FDMT) present at the BofA Securities 2026 Healthcare Conference?

4D Molecular Therapeutics will present at the BofA conference on May 13, 2026 at 1:40 p.m. PT. According to the company, management will also be available for one-on-one investor meetings during the conference and a webcast will be archived for up to one year.

What is the date and time of 4D Molecular Therapeutics (FDMT) presentation at the RBC 2026 Global Healthcare Conference?

The RBC presentation is scheduled for May 19, 2026 at 2:35 p.m. ET. According to the company, management will participate in one-on-one meetings and an archived webcast will be available on the Investors website for up to one year.

Will 4D Molecular Therapeutics (FDMT) make webcasts of the conference presentations available?

Yes. According to the company, archived copies of the webcasts will be available for up to one year on the Investors section of the company website. This provides on-demand access for investors who cannot attend live sessions.

How can investors access 4D Molecular Therapeutics (FDMT) conference webcasts after the events?

Investors can access archived webcasts via the company Investors website for up to one year after the events. According to the company, the webcasts will be posted in the Events section on the 4D Molecular Therapeutics investor relations site.

Will 4D Molecular Therapeutics (FDMT) hold one-on-one investor meetings at the May 2026 conferences?

Yes. According to the company, management will present and participate in one-on-one investor meetings at the May conferences. These meetings are intended to provide direct engagement between management and investors alongside the scheduled presentations.

Where can I find the schedule and details for 4D Molecular Therapeutics (FDMT) investor events in May 2026?

Schedule details list the BofA presentation on May 13, 2026 at 1:40 p.m. PT and RBC on May 19, 2026 at 2:35 p.m. ET. According to the company, full event details and archived webcasts appear on the Investors section of its website.